Treatment of mucous membrane pemphigoid with 0.2% hyaluronic acid gel. Case Report.

Authors

  • Grace Miranda-Becerril Universidad de Ixtlahuaca. Ixtlahuaca de Rayón, México.
  • María del Pilar Suarez-Nava Universidad de Ixtlahuaca. Ixtlahuaca de Rayón, México.
  • Blanca Silvia González-López Centro de Investigación Keisaburo Miyata, Universidad Autónoma del Estado de México, Toluca, México.
  • Julio Cesar Bermudez-Barajas Universidad de Ixtlahuaca. Ixtlahuaca de Rayón, México.
  • Leopoldo Javier Diaz-Arizmendi Instituto de Investigación y Estudios en Salud, Universidad de Ixtlahuaca. Ixtlahuaca de Rayón, México.

DOI:

https://doi.org/10.20453/reh.v32i4.4384

Keywords:

Mucous membrane pemphigoid, rheumatoid arthritis, hyaluronic acid

Abstract

Mucous membrane pemphigoid is a subepithelial, inflammatory, autoimmune blistering disorder that affects the body’s mucous membranes. Most of the cases appear in the oral mucosa. Corticosteroids and antimicrobials are the election treatment. This article describes the efficacy of 0.2% hyaluronic acid gel in mucous membrane pemphigoid. We report a case of a 57-year-old female patient with rheumatoid arthritis and mucous membrane pemphigoid in the upper and lower lips with three months of evolution. Lesions were treated with 0.2% hyaluronic acid gel, obtaining excellent results. The treatment of hyaluronic acid to mucous membrane pemphigoid demonstrated effectiveness in reducing inflammation, pain, and healing of the mucosa, without the need to suspend or adjust the dose of the drugs.

Downloads

Download data is not yet available.

References

Holtsche-MM, Zillikens-D, Schmidt-E. Mucous membrane pemphigoid. 2018;69(1):67–83. DOI: 10.1007/s00105-017-4089-y

Carey-B, Setterfield-J. Mucous membrane pemphigoid and oral blistering diseases. Clin Exp Dermatol. 2019;4(7):732-39. DOI: 10.1111/ced.13996

Sultan-AS, Villa-A, Saavedra-AP, et al. Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study. Oral Dis. 2017 ;23(4):498-504. DOI: 10.1111/odi.12639

Delgado-JC, Turbay-D, Yunis- EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A. 1996;93(16):8569–71. DOI: 10.1073/pnas.93.16.8569

Cytryn-E, Laduron-JC, Colebunders-R, et al. Osophageal stenosis caused by benign mucous membrane pemphigoïd in a patient with an inactive rheumatoïd arthritis. Rofo.1985;142(4):469-70. DOI: 10.1055/s-2008-1052690

Hanaoka-R, Haginoya-T, Koike-M. A case of rheumatoid arthritis complicated with mucous membrane pemphigoid. Mod Rheumatol Case Rep. 2021;5(2):191-194. DOI: 10.1080/24725625.2020.1839196

Kridin-K, Jones-VA, Patel-PM, et al. Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. Immunol Res. 2020;68(6):373–378. DOI: 10.1007/s12026-020-09160-6

Kuten-Shorrer M, Menon-RS, Lerman-MA. Mucocutaneous Diseases. Dent Clin North Am. 2020;64(1):139–62. DOI: 10.1016/j.cden.2019.08.009

Rashid-H, Lamberts-A, Diercks-GFH, et al. Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm. Am J Clin Dermatol. 2019;20(6):847-861. DOI: 10.1007/s40257-019-004

Tirado-Sánchez A. Enfermedades ampollosas autoinmunitarias. Avances importantes. Dermatol Rev Mex. 2019;63(5):439-440.

Velásquez-M, Zamudio-A, González-MI. Administración de gammaglobulina en enfermedades ampollosas graves. Reporte de la experiencia en un hospital universitario, Medellín, Colombia. Dermatol Rev Mex. 2020;64(1):16-25.

Esquivel-Pedraza L, Fernández-Cuevas L, Sánchez-Jiménez YM. Lesiones de la mucosa bucal por administración de metotrexato en paciente con artritis reumatoide. Dermatol Rev Mex. 2017;61(6):492-499.

Porro-AM, Seque-CA, Ferreira-MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019;94(3):264–78. DOI: 10.1590/abd1806-4841.20199011

Shetty-RR, Burde-KN, Guttal-KS. The Efficacy of Topical Hyaluronic Acid 0.2% in the Management of Symptomatic Oral Lichen Planus. J Clin Diagn Res. 2016;10(1):ZC46-50. DOI: 10.7860/JCDR/2016/15934.7101.

Higgins-GT, Allan-RB, Hall-R, et al. Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa. Br J Ophthalmol 2006;90(8):964-7. DOI: 10.1136/bjo.2006.092528

Presta-G, Puliatti-A, Bonetti-L, et al. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report. Int Wound J. 2019;16(6):1433-1439. DOI: 10.1111/iwj.13210

Rodrigo-Royo MD, Quero-López JC, Aparicio-Abiol R. Eficacia de las inyecciones intrarticulares de ácido hialurónico para el tratamiento de la artrosis de rodilla: resultados de una serie de casos tratados en una unidad de dolor. Rev Soc Esp Dolor.2017; 24(2): 74-84. DOI: 10.20986/resed.2016.3485/2016

Friedman-B, Cronstein-B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301-307. DOI: 10.1016/j.jbspin.2018.07.004.

Lee H, Jung-JY, Bang-D. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet’s disease. J Eur Acad Dermatol Venereol. 2008; 22(5):590–5. DOI: 10.1111/j.1468-3083.2007.02564.x

Nolan A, Badminton J, Maguire J, Seymour RA. The efficacy of topical hyaluronic acid in the management of oral lichen planus. J Oral Pathol Med. 2009;38(3):299-303. DOI: 10.1111/j.1600-0714.2008.00739.x

Published

2022-12-15

How to Cite

1.
Miranda-Becerril G, Suarez-Nava M del P, González-López BS, Bermudez-Barajas JC, Diaz-Arizmendi LJ. Treatment of mucous membrane pemphigoid with 0.2% hyaluronic acid gel. Case Report. Rev Estomatol Herediana [Internet]. 2022 Dec. 15 [cited 2024 Dec. 22];32(4):428-34. Available from: http://44.198.254.164/index.php/REH/article/view/4384

Issue

Section

CASE REPORTS